Cost Effectiveness of Arthrocentesis Compared to Conservative Therapy for Arthralgia of the Temporomandibular Joint: A Randomized Controlled Trial

Aims: To determine the cost effectiveness and cost utility of arthrocentesis as an initial treatment for temporomandibular joint (TMJ) arthralgia compared to usual care. Methods: A two-armed, parallel-design, randomized controlled trial (RCT) was conducted in the Netherlands from January 2009 to June 2012 that included patients with TMJ arthralgia. Patients were randomly allocated to arthrocentesis (n = 40) or usual care (n = 40) for initial treatment. Arthrocentesis consisted of rinsing the intra-articular space with isotonic saline, and usual care included a soft diet, physical therapy, and splint therapy. The duration of the usual care program was 6 weeks, and follow-up was conducted 3, 12, and 26 weeks after its completion. Generalized estimated equation multivariate models were assessed in order to correct for the dependency of repeated measurements in the longitudinal data analysis. An independent samples t test was used to compare the arthrocentesis group with the usual care group for TMJ pain after 26 weeks. Cost effectiveness (total cost from a societal view) was related to TMJ pain (as measured on a visual analog scale [0 to 100 mm]) and to cost utility (quality-adjusted life years). Results: TMJ pain declined more quickly in the arthrocentesis group (n = 36) than in the usual care group (n = 36) (regression coefficient β = –10.76; 95% confidence interval [CI] = –17.75 to –3.77; P = .003). The estimated mean total (ie, societal) cost over 26 weeks was €589 (US $795) in the arthrocentesis group and €1,680 (US $2,266) in the usual care group. Arthrocentesis was associated with a lower mean cost and better health outcomes than usual care in 98% and 95% of the bootstrap simulations, respectively. Conclusion: The results of this study suggest that, from an economical perspective, arthrocentesis may be superior to usual care for the initial treatment of TMJ pain, as it had better health outcomes and lower costs than usual care.

arthralgia;arthrocentesis;cost effectiveness;initial therapy;RCT;TMD

1.LeResche L. Epidemiology of temporomandibular disorders: Implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 1997;8:291–305.

2.Schmitter M, Rammelsberg P, Hassel A. The prevalence of signs and symptoms of temporomandibular disorders in very old subjects. J Oral Rehabil 2005;32:467–473.

3.Mienna CS, Wanman A. Self-reported impact on daily life ac-tivities related to temporomandibular disorders, headaches, and neck-shoulder pain among women in a Sami population living in Northern Sweden. J Orofac Pain 2012;26:215–224.

4.Manfredini D, di Poggio AB, Romagnoli M, Dell’Osso L, Bosco M. Mood spectrum in patients with different painful temporo-mandibular disorders. Cranio 2004;22:234–240.

5.Wahlund K. Temporomandibular disorders in adolescents. Epidemiological and methodological studies and a randomized controlled trial. Swed Dent J Suppl 2003;(164):2–64.

6.Gatchel RJ, Garofalo JP, Ellis E, Holt C. Major psychological disorders in acute and chronic TMD: An initial examination. J Am Dent Assoc 1996;127:1365–1374.

7.Jones DA, Rollman GB, Brooke RI. The cortisol response to psychological stress in temporomandibular dysfunction. Pain 1997;72:171–182.

8.White BA, Williams LA, Leben JR. Health care utilization and cost among health maintenance organization members with temporomandibular disorders. J Orofac Pain 2001;15:158–169.

9.Milam SB. Pathogenesis of degenerative temporomandibular joint arthritides. Odontology 2005;93:7–15.

10.de Souza RF, Lovato da Silva CH, Nasser M, Fedorowicz Z, Al-Muharraqi MA. Interventions for the management of tem-poromandibular joint osteoarthritis. Cochrane Database Syst Rev 2012;(4):CD007261.

11.Laskin DM. Arthrocentesis for the treatment of internal de-rangements of the temporomandibular joint. Alpha Omegan 2009;102:46–50.

12.Sorel B, Piecuch JF. Long-term evaluation following temporo-mandibular joint arthroscopy with lysis and lavage. Int J Oral Maxillofac Surg 2000;29:259–263.

13.Currie R. Temporomandibular joint arthrocentesis and lavage. Evid Based Dent 2009;10:110.

14.Nitzan DW, Dolwick MF, Heft MW. Arthroscopic lavage and lysis of the temporomandibular joint: A change in perspective. J Oral Maxillofac Surg 1990;48:798–801.

15.Nitzan DW, Dolwick MF, Martinez GA. Temporomandibular joint arthrocentesis: A simplified treatment for severe, limited mouth opening. J Oral Maxillofac Surg 1991;49:1163–1167.

16.Dimitroulis G, Dolwick MF, Martinez A. Temporomandibular joint arthrocentesis and lavage for the treatment of closed lock: A follow-up study. Br J Oral Maxillofac Surg 1995;33:23–26.

17. Al-Belasy FA, Dolwick MF. Arthrocentesis for the treatment of temporomandibular joint closed lock: A review article. Int J Oral Maxillofac Surg 2007;36:773–782.

18.Monje-Gil F, Nitzan D, González-Garcia R. Temporomandibular joint arthrocentesis. Review of the literature. Med Oral Patol Oral Cir Bucal 2012;17:e575–e581.

19.Kurita K, Westesson PL, Yuasa H, Toyama M, Machida J, Ogi N. Natural course of untreated symptomatic temporomandib-ular joint disc displacement without reduction. J Dent Res 1998;77:361–365.

20.Imirzalioglu P, Biler N, Agildere AM. Clinical and radiological follow-up results of patients with untreated TMJ closed lock. J Oral Rehabil 2005;32:326–331.

21.Stegenga B, de Bont LG, de Leeuw R, Boering G. Assessment of mandibular function impairment associated with temporo-mandibular joint osteoarthrosis and internal derangement. J Orofac Pain 1993;7:183–195.

22.Vos LM, Huddleston Slater JJ, Stegenga B. Arthrocentesis as initial treatment for temporomandibular joint arthropathy: A randomized controlled trial. J Craniomaxillofac Surg 2014; 42:e134–e139.

23.Schiffman EL, Ohrbach R, Truelove EL, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for clinical and research applications: Recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Oral Facial Pain Headache 2014; 28:6–27.

24.Tjakkes GH, Tenvergert EM, de Bont LG, Stegenga B. The ef-fect of intra-articular injection of ultracain in the temporoman-dibular joint in patients with preauricular pain: A randomized prospective double-blind placebo-controlled crossover study. Clin J Pain 2007;23:233–236.

25.Stauffer ME, Taylor SD, Watson DJ, Peloso PM, Morrison A. Definition of nonresponse to analgesic treatment of arthritic pain: An analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale. Int J Inflam 2011;2011:231926.

26.Melzack R, Torgerson WS. On the language of pain. Anesthesiology 1971;34:50–59.

27.Euroqol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

28.Arrindell WA, Ettema J. Symptom Checklist SCL-90. Handleiding bij een multidimensionele psychopathologie-indicator. Lisse: Swets Test, 2003.

29.Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of dis-ease. J Health Econ 1995;14:171–189.

30.Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms relat-ed to productivity costs in economic evaluations of health care programmes. Health Econ 2005;14:435–443.

31.Tan SS, Bouwmans CA, Hakkaart-van Roijen L. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Diemen: College voor zorgverzekeringen, 2010.

32.Siegel JE, Weinstein MC, Russell LB, Gold MR. Recom-mendations for reporting cost-effectiveness analyses. Pan-el on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339–1341.

33.Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–1108.

34.Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993.

35.Black WC. The CE plane: A graphic representation of cost-ef-fectiveness. Med Decis Making 1990;10:212–214.

36. Schiffman EL, Velly AM, Look JO, et al. Effects of four treat-ment strategies for temporomandibular joint closed lock. Int J Oral Maxillofac Surg 2014;43:217–226.

37.Schiffman EL, Look JO, Hodges JS, et al. Randomized effec-tiveness study of four therapeutic strategies for TMJ closed lock. J Dent Res 2007;86:58–63.

38.Tyers MB, Haywood H. Effects of prostaglandins on periph-eral nociceptors in acute inflammation. Agents Actions Suppl 1979;(6):65–78.

39.de Bont LG, Stegenga B. Pathology of temporomandibu-lar joint internal derangement and osteoarthrosis. Int J Oral Maxillofac Surg 1993;22:71–74.

40.Lee JY, Kim DJ, Lee SG, Chung JW. A longitudinal study on the osteoarthritic change of the temporomandibular joint based on 1-year follow-up computed tomography. J Craniomaxillofac Surg 2012;40:e223–e228.

41.Roh HS, Kim W, Kim YK, Lee JY. Relationships between disk displacement, joint effusion, and degenerative changes of the TMJ in TMD patients based on MRI findings. J Craniomaxillofac Surg 2012;40:283–286.